Shermaine Tilley

Partner

7 past transactions

Wattio

Venture Round in 2022
Wattio specializes in the development and sale of advanced home automation devices that enhance comfort, energy efficiency, and security within residences. The company offers a comprehensive smart home solution that integrates various aspects of home management, including electricity usage, comfort controls, and security measures, all managed through a user-friendly platform. Wattio's products feature a scalable and flexible gateway that allows for easy expansion and integration with third-party devices. Designed with simplicity and aesthetic coherence in mind, these gadgets are straightforward to install and operate, complementing home decor while ensuring high-quality performance. By focusing on locally designed and manufactured electronics, Wattio provides high perceived value at competitive prices, enabling consumers to achieve maximum comfort while minimizing energy consumption.

Xagenic

Series B in 2014
Xagenic Inc. is a Toronto-based molecular diagnostics company focused on developing innovative technology for decentralized and rapid diagnostic testing. The company aims to enhance patient care by enabling on-demand, near-patient molecular testing, which allows clinicians to make informed treatment decisions during the initial consultation. Xagenic's technology facilitates rapid, enzyme-free detection of nucleic acids from clinical samples, yielding results in just 20 minutes. By commercializing a simple and fully automated platform, Xagenic is positioned to revolutionize diagnostic testing by enabling it to be conducted outside of traditional clinical laboratories. The company is also working on tests for infectious diseases that provide clinically actionable results in a timely manner, thereby improving overall healthcare efficiency and reducing costs.

Xagenic

Series A in 2012
Xagenic Inc. is a Toronto-based molecular diagnostics company focused on developing innovative technology for decentralized and rapid diagnostic testing. The company aims to enhance patient care by enabling on-demand, near-patient molecular testing, which allows clinicians to make informed treatment decisions during the initial consultation. Xagenic's technology facilitates rapid, enzyme-free detection of nucleic acids from clinical samples, yielding results in just 20 minutes. By commercializing a simple and fully automated platform, Xagenic is positioned to revolutionize diagnostic testing by enabling it to be conducted outside of traditional clinical laboratories. The company is also working on tests for infectious diseases that provide clinically actionable results in a timely manner, thereby improving overall healthcare efficiency and reducing costs.

Zymeworks

Venture Round in 2011
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

Enobia Pharma

Series C in 2009
Enobia Pharma focuses on developing therapies for serious genetic bone disorders that currently lack approved treatments. The company specifically targets conditions such as hypophosphatasia (HPP), a rare metabolic disorder that affects bone mineralization and can lead to severe skeletal deformities and other health complications. Through its innovative research and development efforts, Enobia aims to provide effective solutions for patients suffering from these debilitating conditions.

Zymeworks

Venture Round in 2009
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

BeXcom

Venture Round in 2000
BeXcom, a privately held corporation founded in 1996, operates a global network of eCommerce hubs in the world's major trading zones. This global transaction infrastructure enables companies and exchanges to conduct business electronically locally or with multiple trading partners around the world. BeXcom's Commerce Service Provider model provides and maintains all the required hardware and software to operate centralized B2B eCommerce solutions for their users. By building on the BeXcom infrastructure, supply chains, vertical markets and market makers can quickly implement or dramatically extend their eCommerce capabilities to cover the complete range of purchasing processes, from RFQ to settlement. BeXcom is the first company to integrate global financial, logistics, and certificate authority services into a global eCommerce infrastructure, ensuring all transactions are safe, secure, and verifiable. BeXcom helps their customers streamline business processes, reduce costs, expand markets and add value to their business by delivering the full potential of B2B eCommerce.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.